Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11185505 | 0.98 | CA2 (0.46) | CA2ALDH1A1TSHRTDP1CYP3A4 | |
| SCHEMBL2440934 | 0.95 | CA2 (0.46) | CA2ALDH1A1TSHRTDP1CYP3A4 | |
| SCHEMBL3972402 | 0.92 | GPR84 (0.42) | CA2GPR84FFAR1LMNAMAPT | |
| SCHEMBL3975876 | 0.92 | GPR84 (0.42) | CA2GPR84FFAR1LMNAMAPT | |
| SCHEMBL5157975 | 0.92 | CA2 (0.49) | CA2ALDH1A1TSHRTDP1CYP3A4 | |
| SCHEMBL3969766 | 0.90 | GPR84 (0.43) | CA2GPR84FFAR1LMNAMAPT | |
| SCHEMBL3975370 | 0.90 | GPR84 (0.43) | CA2GPR84FFAR1LMNAMAPT | |
| SCHEMBL141910 | 0.89 | CA2 (0.46) | CA2ALDH1A1TSHRTDP1CYP3A4 | |
| SCHEMBL27998649 | 0.88 | FFAR4 (0.51) | ALDH1A1TSHRTDP1GPR84FFAR1 | |
| SCHEMBL27998450 | 0.88 | FFAR4 (0.51) | ALDH1A1TSHRTDP1GPR84FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100322877-A1 | SILICONE ELASTOMERS IN COSMETIC ESTERS | ALZO INTERNATIONAL, INC. | 2010-12-23 | — | — | US | claimed |
| EP-2211833-A2 | SILICONE ELASTOMERS IN COSMETIC ESTERS | Alzo International, Inc. (US) | 2010-08-04 | — | — | EP | claimed |
| WO-2009054931-A2 | SILICONE ELASTOMERS IN COSMETIC ESTERS | ALZO INTERNATIONAL, INC. (US) | 2009-04-30 | — | — | WO | claimed |
| US-20160194455-A1 | Silicone Elastomer Gels and Related Hydrosilylation Processes | ALZO INT INC (US) | 2016-07-07 | — | — | US | disclosed |
| WO-2015048228-A2 | IMPROVED SILICONE ELASTOMER GELS AND RELATED HYDROSILYLATION PROCESSES | ALZO INTERNATIONAL, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
| WO-2012135281-A2 | SILICONE CROSSLINKED UNSATURATED HYDROCARBON BASED POLYMERS | ALZO INTERNATIONAL, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| US-20100322877-A1 | SILICONE ELASTOMERS IN COSMETIC ESTERS | ALZO INTERNATIONAL, INC. | 2010-12-23 | — | — | US | disclosed |
| EP-2211833-A2 | SILICONE ELASTOMERS IN COSMETIC ESTERS | Alzo International, Inc. (US) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009054931-A2 | SILICONE ELASTOMERS IN COSMETIC ESTERS | ALZO INTERNATIONAL, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100322877-A1 | SILICONE ELASTOMERS IN COSMETIC ESTERS | CUTA, LAGE3, MMS19 | CA2 4205/4885ALDH1A1 2711/4885TSHR 1711/4885 |
| US-20160194455-A1 | Silicone Elastomer Gels and Related Hydrosilylation Processes | ITCH, MMS19, STS | CA2 3593/4885ALDH1A1 1935/4885TSHR 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.